Once-daily timolol formulation OK'd

The FDA has approved a new drug application by ISTA Pharmaceuticals for the once-daily liquid formulation of timolol 0.5% as a therapy for glaucoma.

Related Videos

View All

Related Content

Ocuphire Pharma’s ZETA-1 phase 2 trial of diabetic retinopathy candidate offers mixed results

January 26th 2023

Commercial real estate and your practice, part two with Colin Carr

May 21st 2022

UT Southwestern ophthalmologist shares techniques for cataract surgery complications

January 26th 2023

Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)

May 12th 2022

ARVO announces recipients of 2023 Pfizer Ophthalmics Carl Camras Translational Research Award

January 26th 2023

Expanding gene therapy for Usher Syndrome Type 2A

January 25th 2023

Ocuphire Pharma’s ZETA-1 phase 2 trial of diabetic retinopathy candidate offers mixed results

January 26th 2023

Commercial real estate and your practice, part two with Colin Carr

May 21st 2022

UT Southwestern ophthalmologist shares techniques for cataract surgery complications

January 26th 2023

Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)

May 12th 2022

ARVO announces recipients of 2023 Pfizer Ophthalmics Carl Camras Translational Research Award

January 26th 2023

Expanding gene therapy for Usher Syndrome Type 2A

January 25th 2023

Ocuphire Pharma’s ZETA-1 phase 2 trial of diabetic retinopathy candidate offers mixed results

January 26th 2023

Commercial real estate and your practice, part two with Colin Carr

May 21st 2022

UT Southwestern ophthalmologist shares techniques for cataract surgery complications

January 26th 2023

Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)

May 12th 2022

ARVO announces recipients of 2023 Pfizer Ophthalmics Carl Camras Translational Research Award

January 26th 2023

Expanding gene therapy for Usher Syndrome Type 2A

January 25th 2023

Related Content

---

Ocuphire Pharma’s ZETA-1 phase 2 trial of diabetic retinopathy candidate offers mixed results

Articles

---

Commercial real estate and your practice, part two with Colin Carr

Podcasts

---

UT Southwestern ophthalmologist shares techniques for cataract surgery complications

Articles

---

Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)

Podcasts

---

ARVO announces recipients of 2023 Pfizer Ophthalmics Carl Camras Translational Research Award

Articles

---

Expanding gene therapy for Usher Syndrome Type 2A

Articles